Enjoy complimentary customisation on priority with our Enterprise License!
The global interferons (IFNs) market size is estimated to grow by USD 2.65 billion, at a CAGR of 4.65% between 2023 and 2028. It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.
Viral infections, including hepatitis B and C, respiratory viruses, and emerging threats like Ebola and Zika, pose significant global health risks. Interferons are crucial components of the body's innate immune response, playing a pivotal role in suppressing viral replication and eliminating infected cells. Interferon alpha is extensively used to treat chronic hepatitis infections, leading to improved liver function and viral suppression. Additionally, with concerns surrounding respiratory infections such as influenza and RSV, interferons have been studied for their potential to mitigate severity and duration. Moreover, interferons, notably interferon alpha, are employed in treating viral-related cancers linked to HPV and HTLV-1. As viral threats evolve, effective antiviral interventions are increasingly essential. This drives market growth, as highlighted in studies like those found in the Journal of Medical Virology, bolstered by clinical trial and research studies evaluating drugs like Ribavirin in combating the prevalence of diseases, including chronic diseases like multiple sclerosis and various cancers.
To learn more about this report, Download Report Sample
The market share by the interferon beta segment will be significant during the forecast period. Interferon beta is a protein in the interferon family classified as a type I interferon. It regulates the immune system's response to viral infections and has therapeutic applications in the field of medicine. Interferon beta is produced using biotechnological processes, and recombinant versions are widely used in pharmaceuticals. Interferon beta has significant medical applications, particularly in the treatment of multiple sclerosis. Interferon beta modulates the immune system and has anti-inflammatory properties, which help manage the progression of the disease and alleviate symptoms in multiple sclerosis patients.
Get a glance at the market contribution of various segments Download PDF Sample
The interferon beta segment was valued at USD 3.43 billion in 2018. Several pharmaceutical companies are major producers of interferon beta. Such medications are administered in a variety of ways, including intramuscular or subcutaneous injections, and have become critical components of multiple sclerosis treatment plans. In addition to multiple sclerosis, interferon beta is being investigated for potential applications in other autoimmune disorders and viral infections, demonstrating its versatility and continued relevance in medical research and development. Protein engineering plays a crucial role in the production and optimization of interferon beta variants with enhanced therapeutic properties, such as improved stability or increased bioavailability. These advancements in protein engineering contribute to expanding the application scope of interferon beta in treating various diseases beyond multiple sclerosis. Consequently, the integration of protein engineering technologies is expected to drive growth in the interferons market segment during the forecast period, facilitating the development of more effective and targeted therapies.
The multiple sclerosis?segment will account for the largest share of this segment.?Interferons are commonly used in the treatment of multiple sclerosis owing to their ability to modulate the immune system and reduce inflammation, both of which play important roles in the disease progression. Interferon therapy is intended to reduce the frequency and severity of relapses, slow disability progression, and improve the overall quality of life for people with multiple sclerosis. Furthermore, regular monitoring and assessment are critical for maximizing the benefits of interferon therapy in multiple sclerosis. Thus, such factors will drive the growth of the multiple sclerosis segment in the interferons market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Several factors have influenced the growth of the market in North America, including advances in biotechnology, an increase in the prevalence of diseases that can be treated with interferons, and a strong emphasis on research and development.
Additionally, one of the primary drivers of the interferons market in North America is the high prevalence of autoimmune diseases such as multiple sclerosis. Interferons have emerged as important therapeutic options for treating relapsing forms of multiple sclerosis in the region. The rising incidence of multiple sclerosis, as well as increased awareness of the benefits of interferon-based treatments, all help to drive market growth during the forecast period. Autoinjectors, specifically designed for the self-administration of interferon therapies, play a crucial role in enhancing patient convenience and compliance. These devices enable patients to administer interferons easily and safely at home, contributing to the overall acceptance and utilization of interferon treatments for multiple sclerosis and other autoimmune conditions in North America. Thus, the availability and use of autoinjectors are pivotal in supporting the expanding interferons market in the region.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
3SBio Inc.: The company offers interferons such as Intefen Human Interferon alpha2a Injection for the treatment of lymphatic or hematopoietic malignancies and viral infections.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key trends, and challenges.
Exploration of combination therapies is one of the primary market trends shaping the growth. The development of combination therapies involving interferons and other classes provides a multifaceted approach to improving treatment efficacy across a wide range of medical conditions. This trend stems from the recognition that combining different therapeutic agents can produce synergistic effects, addressing multiple aspects of a disease and potentially improving patient outcomes. The combination of interferons with immunomodulators or targeted therapies is a particularly interesting area.
Moreover, combination therapies, which target multiple pathways or aspects of a disease at the same time, may provide more effective disease control, fewer side effects, and better patient tolerance. Further, as research and clinical trials show the safety and efficacy of combination therapies, this trend is expected to gain traction in the interferons market. Pharmaceutical companies and researchers are likely to investigate and develop novel combinations that maximize the therapeutic potential of interferons, which will propel market expansion during the forecast period.
Side effects and tolerability profiles are a major challenge that affects the market. Interferons, while effective in treating a variety of conditions, frequently cause several side effects that can impair patient adherence, satisfaction, and overall treatment outcomes. Flu-like symptoms, fatigue, and mood swings are common side effects, which can reduce patient quality of life. These side effects may cause noncompliance or discontinuation of treatment, limiting the therapeutic benefits. The impact is especially noticeable in chronic conditions that require long-term or lifelong treatment, such as multiple sclerosis or chronic viral infections.
Furthermore, individual patient's responses to therapy vary, complicating treatment management. Some people may have more severe side effects than others, which affects their ability to tolerate the treatment. This variability can make it difficult for healthcare providers to accurately predict and manage side effects. Addressing these challenges will necessitate ongoing R&D efforts to improve interferon therapy tolerability and patient experiences, ultimately contributing to interferons' long-term growth and acceptance in a variety of medical applications. Thus, such factors will hinder market growth during the forecast period.
The market report includes the adoption lifecycle of the market growth and forecasting, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market research and growth report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
The market report forecasts market growth analysis by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
The market is undergoing significant evolution, spurred by advancements in clinical trial studies and research studies conducted by organizations such as the Journal of Medical Virology and institutions like Pontificia Universidad Católica de Chile. Companies like BetterLife Pharma Inc. and Altum Pharmaceuticals Inc. are pioneering innovative product launches in response to the increasing prevalence of diseases such as cancers and chronic conditions like hepatitis B and multiple sclerosis (MS). Interferons, known for their target affinity and specificity in combating diseases, have gained recognition from authoritative bodies like the American Academy of Pediatrics and the World Health Organization (WHO), particularly in addressing conditions like liver cancer and Hepatitis C virus infection, a significant blood-borne pathogen.
Moreover, with the United States FDA approvals for drugs like PLEGRIDY and BESREMi, the market witnesses increased sales of interferons globally, with government organizations and key players focusing on ensuring FDA approval for interferon-beta solutions and interferon biosimilar medications to cater to the needs of patients, including relapsing multiple sclerosis patients. This dynamic market also sees significant attention on premium-quality manufacturing techniques to meet the demand for biologics licensing and chemically-derived small molecules. Additionally, advancements in kidney transplantation therapeutics are garnering attention, particularly in regions spanning from Equatorial regions of Asia, Africa, and America to countries like Canada and Scotland. These regions are increasingly focusing on developing and approving innovative interferon therapies that may also benefit kidney transplant recipients by potentially reducing rejection rates and improving patient outcomes, expanding the application scope of interferons in medical treatments globally.
|
Interferons Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
160 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4.65% |
|
Market Growth 2024-2028 |
USD 2.65 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
3.89 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 39% |
|
Key countries |
US, UK, Germany, China, and Japan |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
3SBio Inc., Bayer AG, Biogen Inc., Biosidus SA, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Mega Labs SA, Merck KGaA, NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC, Novartis AG, Pfizer Inc., PharmaEssentia Corp., Sanfer, Synairgen plc, and Zydus Lifesciences Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Indication
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.